EuBiologics completes Phase 3 trial of self-developed Covid-19 vaccine

[Courtesy of EuBiologics]

South Korea’s vaccine company EuBiologics Co. has successfully completed Phase 3 trial of an independently-developed Covid-19 vaccine, which will enable the company to ramp up its development in vaccines for other diseases such as typhoid and pneumococcal infections.

According to EuBiologics on Sunday, the Phase 3 trial of its self-developed anti-Covid-19 vaccine EuCorVac-19 has been completed with successful results.

The vaccine maker submitted its data to the health authorities in the Philippines and the Democratic Republic of Congo, where the trial was performed. It will take up to one year until the final results are delivered.

“In the trial for the efficacy of EuCorVac-19, the experimental group exhibited better results in comparison to the control group,” EuBiologics said. “The platform for viral vaccines used in the trial proved successful.”

EuCorVac-19 serves as an instrument of vaccine sovereignty as it is a homegrown vaccine by a Korean pharmaceutical company using solely indigenous platform technology. The global community witnessed the critical importance of securing pharmaceutical independence during the initial stages of the pandemic, with the U.S. government prioritizing vaccine supply for its citizens.

“Like flu shots, Covid-19 vaccinations are likely to be annual in the fight against emerging variants, which explains why homegrown platforms are essential for Korea to adopt such changes,” said an unnamed official from EuBiologics, adding that “development capabilities will allow us to quickly respond to a resurgence of the contagious disease.”

“Our platform features refrigeration systems, compared with mRNA solutions that require cold-chain storage,” the official said.

Founded in 2010, EuBiologics has achieved rapid growth using its vaccine platforms, EuBiologics Vaccine Conjugation Technology (EuVCT) for bacterial vaccines, EuBiologics Immune Modulation Technology (EuIMT) and Spontaneous Nanoliposome Antigen Particle (SNAP) for viral vaccines.

EuVCT, a bacteria-based platform, is a technology that conjugates carrier protein CRM197 to a polysaccharide antigen with the immunogenicity of a specific bacterium.

EuIMT refers to a technology that activates T and B cells to enhance the immune system. SNAP is a drug delivery system working on liposomes.

EuBiologics is expected to tap its latest Covid-19 vaccine platform to accelerate its development of high-quality vaccines against diseases such as typhoid, meningococcal, and pneumococcal diseases by utilizing the innovative EuVCT technology.

Following a successful Phase 3 trial in the Philippines, the company’s experimental typhoid vaccine is undergoing a Phase 3 study in Africa to get pre qualification approval from the World Health Organization (WHO).

The supply of the vaccine to the WHO and UNICEF is expected to begin as early as next year. The pneumococcal vaccine has successfully concluded a Phase 1 study in Korea. In addition, the quadrivalent meningococcal vaccine has also completed its Phase 1 trial in Korea, with the pentavalent vaccine being in Phase 1.

EuBiologics’ EuIMT has been used for the development of vaccines against respiratory syncytial virus (RSV) and Herpes zoster virus (HZV).